Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5794041 | 0.98 | GAA (0.38) | GAAL3MBTL1KDM4EMAOBKMT2A | |
| SCHEMBL10102109 | 0.78 | MAOA (0.32) | MAOBMAOA | |
| SCHEMBL7634036 | 0.78 | GAA (0.40) | GAAL3MBTL1KDM4EKMT2A | |
| SCHEMBL18329616 | 0.74 | GAA (0.40) | GAAL3MBTL1KDM4EKMT2A | |
| SCHEMBL5400361 | 0.74 | GAA (0.40) | GAAL3MBTL1KDM4EKMT2A | |
| SCHEMBL2962376 | 0.74 | GAA (0.40) | GAAL3MBTL1KDM4EKMT2A | |
| SCHEMBL2963209 | 0.74 | GAA (0.40) | GAAL3MBTL1KDM4EKMT2A | |
| SCHEMBL5697706 | 0.73 | GAA (0.39) | GAAL3MBTL1KDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL5048328 | 0.73 | GAA (0.42) | GAAL3MBTL1KDM4EKMT2A | |
| SCHEMBL12385241 | 0.72 | GAA (0.46) | GAAL3MBTL1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006014968-A2 | PROPARGYL NITROXYDES AND INDANYL NITROXIDES AND THEIR USE FOR THE TREATMENT OF NEUROLOGIC DISEASES AND DISORDERS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006014968-A2 | PROPARGYL NITROXYDES AND INDANYL NITROXIDES AND THEIR USE FOR THE TREATMENT OF NEUROLOGIC DISEASES AND DISORDERS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025446-A1 | Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025446-A1 | Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders | CBR1, NR1H2, NR1H3 | GAA 3240/4885L3MBTL1 363/4885KDM4E 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.